

# Loss of METTL3 attenuates blastic plasmacytoid dendritic cell neoplasm response to PRMT5 inhibition via IFN signaling

Malini Rethnam,<sup>1</sup> Darren Qiancheng Tan,<sup>1</sup> Shi Hao Tan,<sup>1</sup> Jia Li,<sup>1</sup> Rui Yokomori,<sup>1</sup> Ying Li,<sup>1</sup> Henry Yang,<sup>1</sup> Takaomi Sada,<sup>1</sup> and Toshio Suda<sup>1,2</sup>

<sup>1</sup>Cancer Science Institute of Singapore, National University of Singapore, Singapore; and <sup>2</sup>International Research Center for Medical Sciences, Kumamoto, Japan

## Key Points

- PRMT5 is highly expressed in BPDCN, and pharmacological inhibition of PRMT5 activity disrupts splicing of key RNA methylation genes.
- Depletion of *METTL3* diminishes BPDCN cell response to PRMT5 inhibition due to elevated IFN signaling mediated via the *IRF7-IFIT1* axis.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy with poor clinical outcomes. Dysregulated *MYC* expression, which is associated with protein arginine methyltransferase 5 (PRMT5) dependency, is a recurrent feature of BPDCN. Although recent studies have reported a *PRMT5* gene signature in BPDCN patient samples, the role of PRMT5 in BPDCN remains unexplored. Here, we demonstrate that BPDCN is highly sensitive to PRMT5 inhibition. Consistent with the upregulation of *PRMT5* in BPDCN, we show that pharmacological inhibition (GSK3326595) of PRMT5 inhibits the growth of the patient-derived BPDCN cell line CAL-1 in vitro and mitigated tumor progression in our mouse xenograft model. Interestingly, RNA-sequencing (RNA-seq) analysis revealed that PRMT5 inhibition increases intron retention in several key RNA methylation genes, including *METTL3*, which was accompanied by a dose-dependent decrease in *METTL3* expression. Notably, the function of cellular m<sup>6</sup>A RNA modification of *METTL3* was also affected by PRMT5 inhibition in CAL-1 cells. Intriguingly, *METTL3* depletion in CAL-1 caused a significant increase in interferon (IFN) signaling, which was further elevated upon PRMT5 inhibition. Importantly, we discovered that this increase in IFN signaling attenuated the sensitivity of *METTL3*-depleted CAL-1 cells to PRMT5 inhibition. Correspondingly, stimulation of IFN signaling via TLR7 agonists weakened CAL-1 cell sensitivity to PRMT5 inhibition. Overall, our findings implicate PRMT5 as a therapeutic target in BPDCN and provide insight into the involvement of *METTL3* and the IFN pathway in regulating the response to PRMT5 inhibition.

## Introduction

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically aggressive myeloid malignancy with a poor prognosis.<sup>1–3</sup> BPDCN stems from transformed plasmacytoid dendritic cells (pDCs), which overexpress interleukin-3 receptor subunit  $\alpha$  (IL3RA or CD123).<sup>1,4</sup> This disease exhibits similar molecular characteristics to acute myeloid leukemia (AML) and myelodysplastic syndrome<sup>1</sup> and hence has been often misdiagnosed. BPDCN is diagnosed based on the expression of specific surface markers (CD123, CD4, and CD56). The median survival of BPDCN patients is <2 years,<sup>2,3</sup> and relapse is frequent despite high-dose chemotherapy and hematopoietic stem cell transplantation.<sup>3,5</sup> In 2018, the US Food and Drug Administration approved tagraxofusp-erzs, a CD123-directed cytotoxin for BPDCN treatment.<sup>2,4,6</sup> However, tagraxofusp-erzs has major adverse effects despite initial promising clinical outcomes.<sup>4,6</sup> Hence, there is an urgent clinical need to discover novel therapeutic options for BPDCN.

Submitted 6 October 2021; accepted 8 April 2022; prepublished online on *Blood Advances* First Edition 28 April 2022; final version published online 21 September 2022. DOI 10.1182/bloodadvances.2021006306.

For data sharing, contact the corresponding author: csits@nus.edu.sg.

The full-text version of this article contains a data supplement.

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Protein arginine methyltransferases (PRMTs) are ubiquitously expressed and serve as writers of arginine methylation, a type of post-translational modification essential for the functional diversity of proteins.<sup>7-9</sup> Nine PRMTs and 3 types of methylarginine species ( $\omega$ -*NG*-monomethylarginine;  $\omega$ -*NG*, *NG*-asymmetric dimethylarginine; and  $\omega$ -*NG*, *N'*-G-symmetric dimethylarginine [SDMA]) have been reported.<sup>7,9</sup> PRMT5 is the major arginine methyltransferase that catalyzes SDMA on substrates, which contributes to its role in regulating diverse functions, including alternative splicing and cell proliferation.<sup>7,9-11</sup> PRMT5 overexpression is often implicated in solid and hematologic malignancies,<sup>12-14</sup> and its pharmacological inhibition was found to improve the prognosis of patients with AML and myelodysplastic syndrome.<sup>10,15</sup>

Transcriptionally, BPDCN patient samples and the patient-derived cell line (CAL-1) were found to exhibit a gene expression signature enriched for genes regulated by PRMT5, a key regulator of splicing.<sup>11,16</sup> BPDCN patient samples were also shown to exhibit a gene signature for MYC targets and found to overexpress MYC.<sup>17</sup> Interestingly, dysregulated MYC expression was reported to render B-cell lymphoma cells more dependent on PRMT5 for splicing fidelity maintenance.<sup>18</sup> Furthermore, several splicing factors were found to be frequently mutated in BPDCN.<sup>19</sup> Therefore, we hypothesize that PRMT5 is an important therapeutic target in BPDCN and contributes to the molecular pathogenesis of BPDCN.

In this study, we evaluated the role of PRMT5 in BPDCN, the potential of PRMT5 as a therapeutic target in BPDCN, and how the expression of methyltransferase-like protein 3 (*METTL3*), a writer of m<sup>6</sup>A modification on RNA,<sup>20-22</sup> determines BPDCN cell response to PRMT5 inhibition. Overall, our findings have identified a new therapeutic target in BPDCN and uncovered a unique interconnection among PRMT5, *METTL3*, and interferon (IFN) signaling pathways, which has not been reported in hematological malignancies like BPDCN.

## Materials and methods

### Cell lines and cell culture

CAL-1, a BPDCN patient-derived cell line,<sup>23</sup> was cultured as previously described.<sup>5,23</sup> Leukemic cell lines were purchased from ATCC. All cell lines were cultured with RPMI1640 (Biowest), supplemented with 10% fetal bovine serum (FBS) (Biowest) and 1% antibiotic-antimycotic (Gibco). 293T cells were cultured in high-glucose Dulbecco's Modified Eagle Medium (Biowest), supplemented with 10% FBS and 1% penicillin-streptomycin (Gibco). Cells were cultured at 37°C in humidified conditions with 5% CO<sub>2</sub>.

### Mice models

Male NOD SCID Gamma (NSG) mice at 7 to 8 weeks old purchased from The Jackson Laboratory were used for CAL-1 xenograft experiments. *TET2*<sup>Δ/Δ</sup> *P53*<sup>Δ/Δ</sup> DKO + *MYC RUNX2* OE, a de novo BPDCN mouse model was generated by Kubota and colleagues (2019).<sup>5</sup> RNA-sequencing (RNA-seq) data obtained from leukemic cells from this mouse model were used for gene expression analyses.

### CAL-1 xenograft and drug treatment

CAL-1 xenografts were established as previously reported.<sup>24</sup> Briefly, NSG mice were subcutaneously engrafted with  $1 \times 10^6$  of CAL-1

cells and resuspended in 1:1 phosphate-buffered saline/Matrigel (Corning) suspension. Engrafted mice were randomly assigned into control or treatment groups, and treatment commenced once tumors reached an average of 100 mm<sup>3</sup>. Mice in the treatment group received 150 mg/kg of GSK3326595 (Hy-101563I MedChemExpress) bidaily via oral gavage, while the control group received 0.5% methylcellulose. Weight, tumor growth, and overall mice condition were monitored daily until a humane endpoint. All experimental procedures were reviewed and approved by the Institutional Animal Care and Use Committee of the National University of Singapore.

### Vectors and lentivirus infections

pLV-U6-hMETTL3, pLV-U6-hMETTL14, pLV-U6-hPRMT5, pLV-U6-hPRMT1, pLV-U6-hPRMT4 short hairpin RNA (shRNA) vectors and pLV-EF1A-FLAG/hPRMT5, *METTL3* overexpressing vectors were designed and purchased from VectorBuilder. Lentiviruses were produced by cotransfecting 293Ts with shRNA vector and packaging plasmids using FuGENE 6 transfection reagent (Promega). Lentivirus supernatants were harvested and filtered before infecting CAL-1 cells via spin infection. Positively infected cells (GFP<sup>+</sup> or mCherry<sup>+</sup> cells) were isolated by fluorescence-activated cell sorting (FACS) 72 hours after infection.

### CRISPR-CAS9 *METTL3* knockout (KO)


CAL-1 cells were first transduced with FUCas9Cherry (#70182; Addgene) using the above-described lentivirus infection. *METTL3* single guide RNA (sgRNA) sequences were obtained from GPP (Genetic Perturbation Platform) web portal (<https://portals.broadinstitute.org/gpp/public/>) and cloned into FgH1tUTG (#70183; Addgene). CAL-1 Cas9 cells were then infected with either *NT*, *METTL3*, or *AAVS1* sgRNA plasmids, and double-positive cells (GFP<sup>+</sup> and mCherry<sup>+</sup>) were isolated by FACS after 72 hours. *METTL3* KO was induced with 3 μg/mL doxycycline (#24390-14-5; Sigma) for 48 hours. FUCas9Cherry and FgH1tUTG plasmids were gifts from Marco Herold (RRID: Addgene\_70182 and RRID: Addgene\_70183).

### Western blotting

Cell pellets were lysed in 1× Laemmli buffer and heated at 95°C. Lysates were then sonicated for protein extraction, and supernatants were quantified via bicinchoninic acid protein assay (Thermo Fisher Scientific). Protein was resolved by 4% to 20% gradient gels (Bio-rad) and transferred to polyvinylidene difluoride membranes. Blots were blocked with 5% bovine serum albumin and incubated overnight at 4°C with antibodies against PRMT5 (ab109451; Abcam), SDMA (13222S; Cell signaling), *METTL3* (ab195352; Abcam), *METTL14* (ABE1338; Millipore), cleaved caspase-3 (#9664; Cell signaling), c-MYC (#5605; Cell signaling), or β-Actin-HRP (A5441; Sigma). After washing, membranes were incubated with secondary antibodies for 1 hour at RT. Blots were developed using Western Lightning ECL Pro (Perkin Elmer) and imaged on Chemi-doc imaging system.

### In vitro proliferation and viability assay

CAL-1 and AML cells were seeded at appropriate densities and treated with increasing concentrations of GSK3326595 (HY-101563; MedChemExpress), with dimethyl sulfoxide (DMSO) as control. Percentage viable and number of cells were determined using trypan blue exclusion and counted with an automated cell counter (Thermo Fisher



**Figure 1. PRMT5 is highly expressed in BPDCN, and its inhibition perturbs cell growth.** (A) BPDCN cell lines (CAL-1 and Gen2.2) express elevated levels of *MYC* and *PRMT5* as compared with healthy pDCs. (B) High levels of *PRMT5* in de novo BPDCN mouse model (*TET2*<sup>-/-</sup> *P53*<sup>-/-</sup> DKO + *MYC* *RUNX2* OE). (C) mRNA and (D) protein expression of *PRMT5* after 72 hours of shRNA KD. (E) Growth of CAL-1 after *PRMT5* KD, cell counts normalized to scrambled. (F) mRNA expression of *PRMTs*, 72 hours after shRNA KD. (G) Growth of CAL-1 after *PRMT1*, 4, or 7 KD, cell counts normalized to scrambled. (H) A dose-dependent decrease in CAL-1, MOLM-13, and THP-1 growth 72 hours after GSK595 treatment. Data are shown as mean  $\pm$  standard error of the mean of 3 independent experiments. \**P* < .05; \*\**P* < .01; \*\*\**P* < .001.

Scientific). Cells were then harvested and pelleted down for protein and RNA analyses.

### Annexin-V/hoechst assay

GSK3326595-treated cells were harvested and resuspended in annexin V binding buffer (#51-66121E; BD) and centrifuged. Pellets were resuspended in a suspension comprising annexin V-APC

(A35110; Invitrogen) and Hoechst 33258 dye (H3569; Life Technologies), and apoptotic fraction was analyzed using FACS.

### m<sup>6</sup>A enzyme-linked immunoassay (ELISA)

CAL-1 cells were harvested after GSK3326595 treatment and RNA was extracted. m<sup>6</sup>A ELISA (#185912; Abcam) was performed using 200 ng of RNA, according to the manufacturer's protocol.




Figure 2.

Each biological replicate was done in triplicates, and 3 biological replicates were performed.

### TLR7 agonists and GSK595 cotreatment

CAL-1 cells were seeded at a density of  $6 \times 10^4$ /mL in a 6-well plate. Subsequent cells were stimulated with either resiquimod, gardiquimod, or imiquimod and treated with 0.31 and 5  $\mu$ M of GSK3326595. Cells were concurrently harvested for downstream analyses and also stained for BPDCN markers for phenotypic analysis via FACS.

### RNA extraction and gene expression analysis

RNA was extracted using RNeasy Micro or Mini kit (Qiagen) according to the manufacturer's protocol, and complementary DNA (cDNA) was synthesized from extracted RNA using EVO Script Universal cDNA Master (#07912455001; Roche). PowerUp Sybr Green (#A25742; Invitrogen) was used for quantitative reverse transcription polymerase chain reaction (PCR) and was performed on the QuantStudio 3 Real-Time PCR system (Thermo Fisher Scientific). Primers used are listed in supplemental Table 1.

Analysis was performed using the comparative threshold cycle method ( $2^{-\Delta\Delta C_t}$ ). Gene expression levels were normalized to housekeeping genes (Actin).

### RNA-seq and analysis

Total RNA from GSK3326595-treated CAL-1 cells and *METTL3* KO cells was extracted using TRIzol. Library preparation was performed using the Illumina TruSeq Stranded messenger RNA (mRNA) kit. NovaSeq6000 sequencer was used for 150 bp paired-end sequencing. RNA-seq data reads were mapped to the human hg38 genome, and differentially expressed genes (DEGs) between DMSO and GSK3326595-treated CAL-1 cells were identified using the following cutoff values: fold-change of 2 and an adjusted *P* value of .05. For splicing analysis, the difference in splice index was used to identify differential splicing events between DMSO and GSK3326595-treated CAL-1 cells. These differential splicing events were subsequently clustered into intron retention (IR), exon skipping, or cryptic splice based on the annotation from the University of California Santa Cruz Refseq library.

A similar approach was taken for the analysis of *METTL3* KO cells, where DEGs between wild type (WT) and *METTL3* KO were identified. Gene set enrichment was used to identify enriched gene sets between (1) DMSO and GSK3326595-treated CAL-1 and (2) WT and *METTL3* KO. RNA-seq reads were mapped to transcript sequences of curated RefSeq (NM and NR transcripts) using salmon (version 1.4.0)<sup>25</sup> with the options “-gcBias -seqBias -posBias.” The index file for the transcript sequences was created with default settings. Transcript-level read counts were converted to gene-level read counts using tximport (version 1.18.0).<sup>26</sup> DEGs were estimated using DESeq2 (version 1.30.0).<sup>27,28</sup>

### Splice variant expression analysis

cDNA was synthesized as described above and amplified by PCR using Go Taq G2 Hot Start Green Master Mix (M5122; Promega). Primers flanking the intron region of interest were designed based on sites identified from RNA-seq data (supplemental Table 1). Amplified products were resolved by agarose gel electrophoresis and visualized using Gel Doc XR+ system (Biorad).

### Statistical analysis

All data are represented as mean  $\pm$  standard deviation unless otherwise stated. Number of biological replicates are included in figure legends. Statistical analyses were calculated using Student 2-tailed paired *t* test.

## Results

### PRMT5 is essential in BPDCN, and pharmacological inhibition of PRMT5 induces apoptosis and mitigates tumor growth


To evaluate the potential of PRMT5 as a therapeutic target in BPDCN, we first analyzed *PRMT5* and *MYC* mRNA expression in BPDCN cells and normal healthy donor pDCs. Compared with the pDCs, *PRMT5* and *MYC* levels were significantly elevated in BPDCN patient-derived cell lines (CAL-1 and Gen2.2) (Figure 1A). Similarly, analysis of *PRMT5* levels from RNA-seq data obtained from a previously established murine BPDCN model (*Tet2*<sup>Δ/Δ</sup>; *Trp53*<sup>Δ/Δ</sup> double KO with *Myc* and *Runx2* overexpression)<sup>5</sup> showed elevated expression compared with normal mouse pDCs (Figure 1B). These show that *PRMT5* is highly expressed in BPDCN cells.

We next analyzed the effect of PRMT5 inhibition in CAL-1 cells, a *MYC*-dependent BPDCN patient-derived cell line.<sup>23</sup> Genetic knock-down (KD) of *PRMT5* using 2 independent shRNA successfully reduced PRMT5 expression at mRNA and protein levels in CAL-1 cells (Figure 1C-D). Notably, *PRMT5* KD significantly suppressed CAL-1 cell growth by ~50% to 60% (Figure 1E). In contrast, KD of other PRMT family members (*PRMT1*, *PRMT4*, and *PRMT7*) (Figure 1F) had no significant impact on CAL-1 cell growth (Figure 1G). Importantly, overexpression of PRMT5 before shRNA-mediated PRMT5 KD rescued the decrease in CAL-1 cell growth, thus excluding the possibility of off-target KD (supplemental Figure 1A-D). These illustrate that PRMT5 is specifically essential for BPDCN cell growth.

We then assessed the sensitivity of BPDCN to pharmacological inhibition of PRMT5 by comparing the response between CAL-1 and 3 AML cell lines (THP-1, MOLM-13, and MV-4-11) to treatment with the well-characterized PRMT5 inhibitor GSK3326595 (GSK595).<sup>15</sup> GSK595 is a highly selective and potent small-molecule inhibitor of PRMT5, which binds to the catalytic site of PRMT5. This results in inhibition of the methyltransferase activity of PRMT5, causing a decrease in SDMA modifications on downstream

**Figure 2 (continued) Pharmacological inhibition of PRMT5 induces apoptosis and mitigates tumor growth.** (A) Treatment of BPDCN (CAL-1) and AML (THP-1, MOLM-13, MV-4-11) cells with GSK3326595. Decrease in (B) *PRMT5* and (C) *MYC* mRNA expression after 72 hours of treatment. (D) Reduction in SDMA levels upon GSK595 treatment. (E) A dose-dependent increase in apoptotic fraction after treatment. (F) Expression of anti (*BCL-2*) and proapoptotic (*PUMA*) genes in GSK595-treated CAL-1 cells, normalized to DMSO. (G) Schematic illustration of treatment regimen (created with BioRender.com) (H) Decrease in tumor volume in GSK595-treated mice compared with vehicle-treated. (I) Loss of SDMA expression in tumors harvested from treated mice. (J) Mice body weight upon treatment with vehicle or GSK595. Data are shown as mean  $\pm$  standard error of the mean of 3 independent experiments. \**P* < .05; \*\**P* < .01; \*\*\**P* < .001.





**Figure 3. PRMT5 inhibition causes increased IR in genes associated with RNA methylation.** (A) Increase in IR events in the treated group compared to the DMSO control group. (B) Biological processes are overrepresented among genes with increased IR. (C) GSEA plots illustrating gene sets affected by GSK595 treatment. (D) Decrease in expression of genes associated with RNA methylation after treatment with GSK595 (0.31 and 5  $\mu$ M). (E) A dose-dependent increase in IR transcripts of *METTL3* after PRMT5 inhibition. Decrease in (F) mRNA expression of *PRMT5* and *METTL3* (normalized to DMSO) and (G) protein levels of PRMT5, METTL3, MYC, and cleaved caspase-3 after GSK595 treatment. (H) Dose-dependent reduction in m<sup>6</sup>A activity in treated cells normalized to DMSO. Data are shown as mean  $\pm$  standard error of the mean of 3 independent experiments. \* $P$  < .05; \*\* $P$  < .01. GSEA, gene set enrichment.

targets.<sup>7,15</sup> Compared with THP-1, which is relatively resistant to PRMT5 inhibition,<sup>29</sup> the growth IC<sub>50</sub> (glC<sub>50</sub>) of CAL-1 was ~30-fold lower (Figure 2A). Notably, the sensitivity of CAL-1 to GSK595 was comparable to MOLM-13 (Figure 2A), which was previously shown to be highly sensitive to PRMT5 inhibition.<sup>29</sup> In agreement, GSK595 induced net cell death in CAL-1 and MOLM-13

cells, but not THP-1, at concentrations above 0.31  $\mu$ M over 5 days (Figure 1H).

We then confirmed that the growth inhibition of CAL-1 by GSK595 was associated with a dose-dependent reduction in *PRMT5* (Figure 2B) and MYC expression (Figures 2C and 3G), accompanied




Figure 4.

by a decrease in the functional activity of PRMT5 (ie, SDMA modification) (Figure 2D). Importantly, PRMT5 inhibition induced significant apoptosis, reflected by increased levels of the apoptosis marker cleaved caspase-3 (Figure 2D) and an increased proportion of annexin-V–positive cells (Figure 2E). This was also accompanied by reduced expression of the antiapoptotic gene *BCL-2* and increased expression of the proapoptotic gene *PUMA* (Figure 2F).

We next evaluated the in vivo efficacy of PRMT5 inhibition on BPDCN. We established a mouse xenograft model by subcutaneously injecting CAL-1 cells into NSG mice and then orally administered either GSK595 (150 mg/kg body weight) or vehicle (0.5% methylcellulose) bidaily (Figure 2G). Notably, drug treatment suppressed tumor growth at day 6, as shown by the significantly reduced tumor volume in GSK595-treated mice compared with vehicle-treated mice (Figure 2H). This was associated with in vivo target inhibition, as shown by the decreased levels of SDMA-modified proteins in tumors harvested from GSK595-treated mice (Figure 2I). GSK595 was also well-tolerated, with minimal changes in body weight throughout the treatment period (Figure 2J). Taken together, these findings indicate that PRMT5 activity is essential for the growth and survival of MYC-driven BPDCN and suggest that PRMT5 is a potential therapeutic target in BPDCN.

### PRMT5 inhibition causes increased IR in genes associated with RNA methylation

To elucidate the molecular mechanisms underlying the observed cell growth inhibition of MYC-driven BPDCN cells upon PRMT5 inhibition, we performed a transcriptome analysis of GSK595-treated CAL-1 cells. Consistent with prior reports on the role of PRMT5 in regulating RNA splicing,<sup>11,14,29-31</sup> PRMT5 inhibition in CAL-1 cells was associated with a significant increase in IR events (Figure 3A). Intriguingly, we found that biological processes associated with DNA repair, cell division, and RNA methylation were significantly overrepresented among these upregulated IR events (Figure 3B).

These observations prompted us to focus our investigation on RNA methylation. Correspondingly, gene set enrichment with curated gene sets demonstrated that the target genes of *METTL14*, a core component of the m<sup>6</sup>A methyltransferase complex, were found to be coordinately downregulated in GSK595-treated CAL-1 cells (Figure 3C). *METTL14* forms the Methyltransferase complex (MTC) together with *METTL3*, and the MTC is responsible for performing m<sup>6</sup>A modification on mRNAs.<sup>21,32,33</sup> Although *METTL14* expression was not significantly changed in CAL-1 cells after GSK595 treatment, the catalytic component of the MTC, namely *METTL3*, was significantly downregulated (Figure 3D,F). Strikingly, GSK595 treatment was associated with a dose-dependent increase in *METTL3* IR events in CAL-1 cells (Figure 3E), corroborating the in silico observation of increased IR events in GSK595-treated CAL-1 cells. In agreement with evidence indicating that IR events generally reduce protein expression,<sup>30</sup> we also observed a corresponding

dose-dependent decrease in *METTL3* protein levels in GSK595-treated CAL-1 cells (Figure 3G).

To determine if dysregulated *METTL3* expression caused by PRMT5 inhibition affects cellular RNA modification function, we performed an ELISA-based assay using RNA from GSK595-treated CAL-1 cells and found that the levels of m<sup>6</sup>A RNA modification decreased in a dose-dependent manner (Figure 3H). Therefore, these findings indicate that PRMT5 inhibition in BPDCN perturbs RNA splicing of the *METTL3* gene, which in turn affects multiple biological processes, including cellular m<sup>6</sup>A RNA methylation.

### *METTL3* depletion attenuates the effect of PRMT5 inhibition on BPDCN cells

Given the above findings, we next sought to understand the requirement of m<sup>6</sup>A RNA methylation in MYC-driven BPDCN cells. Notably, shRNA-mediated KD of *METTL3* or *METTL14* significantly affected CAL-1 cell growth (Figure 4A-B). Interestingly, KD of *METTL3* affected the expression of *METTL14* and vice versa (Figure 4A). As both these genes are key components in the MTC,<sup>34</sup> we speculate that targeting one component affects the expression of the other. Next, we used a doxycycline-inducible CRISPR-CAS9 system as validation and observed that CAL-1 cell growth was significantly suppressed upon *METTL3* KO (Figure 4C-E). These observations indicate that m<sup>6</sup>A RNA methylation machinery is likely required for the growth of MYC-driven BPDCN cells.


To study how *METTL3* depletion influences CAL-1 cell response to PRMT5 inhibition, we induced *METTL3* KO with doxycycline and simultaneously treated the cells with GSK595. Similar to PRMT5 inhibition, we observed a dose-dependent decrease in the expression of PRMT5, *METTL3*, and c-MYC (Figure 4F,H). Surprisingly, *METTL3* KO cells were approximately 30% to 40% less sensitive to GSK595 as compared with nontargeting (NT; scramble sgRNA) controls (Figure 4G). Correspondingly, GSK595-induced apoptosis of CAL-1 cells was suppressed upon *METTL3* KO; as evidenced by the reduced levels of cleaved caspase-3 (Figure 4H), reduced *PUMA* expression (Figure 4I), and lower proportion of annexin-V–positive cells (Figure 4J). Taken together, these results indicate that *METTL3* depletion attenuates the sensitivity of MYC-driven BPDCN cells to PRMT5 inhibition.

### Loss of *METTL3* induces IFN signaling upon PRMT5 inhibition

To elucidate the mechanisms underlying this unique phenomenon, we analyzed the transcriptomes of *METTL3*-depleted CAL-1 cells in the presence and absence of GSK595 by RNA-seq. Analysis of the DEGs between *METTL3* WT (noninduced) and *METTL3* KO (Dox-induced) CAL-1 cells revealed that upregulated DEGs in *METTL3*-depleted cells were highly enriched for genes associated with the IFN- $\alpha$  and IFN- $\gamma$  response pathways (Figure 5A). In

**Figure 4 (continued) *METTL3* depletion attenuates the effect of PRMT5 inhibition on BPDCN cells.** (A) Reduction in mRNA expression of *METTL3* and *METTL14* after 72 hours of shRNA KD (normalized to NT). (B) CAL-1 cell growth after 72 hours shRNA KD, normalized to NT. (C) Expression of *METTL3* upon KO induction with 2 independent *METTL3* sgRNAs (72 hours, 3  $\mu$ g/mL Dox). (D) mRNA expression of *METTL3*, 72 hours after Dox induction, normalized to NT. (E) CAL-1 cell growth after *METTL3* KO (72 hours, 3  $\mu$ g/mL Dox), normalized to noninduced. (F) mRNA expression of *PRMT5* and *METTL3* in GSK595-treated KO cells. (G) Cell growth of CAS9 and *METTL3* KO cells after GSK595 treatment, normalized to DMSO. (H) Lack of cleaved caspase-3 activation upon treatment in KO cells only. (I) mRNA expression of *PUMA* in GSK595-treated KO cells. (J) Quantification of the apoptotic fraction. Data are shown as mean  $\pm$  standard error of the mean of 3 independent experiments. \**P* < .05; \*\**P* < .01; \*\*\**P* < .001.





**Figure 5. Loss of *METTL3* induces IFN signaling upon *PRMT5* inhibition.** (A) Enriched pathways within upregulated genes in KO cells (analyzed using “Enrichr”; <https://maayanlab.cloud/Enrichr/>). (B) Volcano plot depicting up and downregulated genes upon *METTL3* KO. (C) Heatmap showing the expression pattern of IFN pathway signaling genes. Z-scores were calculated for each gene using DESeq2 normalized counts. Gene expression clustering was performed using the Euclidean distance and complete linkage method. mRNA expression of (D) *IFIT* genes and (E) *IRFs* in WT, *METTL3* KO - DMSO and GSK595-treated cells (normalized to WT DMSO). (F) Validation of *METTL3* overexpression in CAL-1 cells. (G) Expression of *IFIT1* in WT and *METTL3* OE cells after GSK595 treatment. Data are shown as mean  $\pm$  standard error of the mean of 3 independent experiments. \* $P < .05$ ; \*\* $P < .01$ ;  $P < .001$ .




Figure 5. (continued)


addition, among the DEGs between *METTL3* KO and WT control cells, we observed that several IFN-associated genes such as *OAS1*, *OAS2*, and *IFIT1* were highly and significantly upregulated in *METTL3*-depleted CAL-1 cells (Figure 5B). In agreement, a comparison of IFN signaling-associated genes across 4 settings (*METTL3* WT cells treated with DMSO, *METTL3* WT cells treated with GSK595, *METTL3* KO cells treated with DMSO, and *METTL3* KO cells treated with GSK595) revealed an upregulation of multiple IFN-associated genes upon *METTL3* KO (Figure 5C). Notably, the expression of these IFN-associated genes was further upregulated in GSK595-treated *METTL3* KO cells (Figure 5C). This compelled further investigation into the IFN signaling pathway and how this regulates response to PRMT5 inhibition.

It is noteworthy that *PRMT5* has been reported to regulate IFN signaling, whereas SDMA modification supports the upregulation of IFN stimulated genes, including the *IFIT* gene family.<sup>35</sup> Thus, we examined the expression of various *IFIT* gene family members. In particular, *IFIT1* was significantly upregulated upon *METTL3* KO (Figure 5D), and its expression further increased after GSK595 treatment (Figure 5C-D). Importantly, *IFIT1* upregulation was not observed upon doxycycline induction of NT scramble sgRNA (supplemental Figure 2A). To clarify the relationship between IFN response and *METTL3* in the context of PRMT5 inhibition, we next examined the key transcriptional regulators of *IFIT1*.<sup>36-38</sup> Among the various IRF genes which regulate *IFIT1*, *IRF7* was found to be predominantly expressed by pDCs, as compared with other immune cell types (supplemental Figure 3A) and was reported to be

upregulated in colorectal cancer upon *METTL3* depletion.<sup>39</sup> In agreement, we found that *IRF7*, but not the other *IRF* family members, was significantly upregulated after *METTL3* KO and GSK595 treatment (Figure 5E). In contrast, *IRF7* was not upregulated upon doxycycline induction of NT scramble sgRNA (supplemental Figure 2B). To corroborate these results, we overexpressed *METTL3* in CAL-1 cells (Figure 5F) and observed that *METTL3* overexpression suppressed *IFIT1* expression, which was further reduced upon GSK595 treatment (Figure 5G).

We further verified the specificity of *METTL3* KO on IFN signaling via KO of the safe harbor locus *AAVS1*. Unlike *METTL3* KO, *AAVS1* KO in CAL-1 did not suppress cell growth (supplemental Figure 2C-D). Instead, there was a dose-dependent decrease in cell growth of *AAVS1* KO cells in response to GSK595 treatment (supplemental Figure 2E). Unexpectedly, we observed an upregulation of *IRF7* and *IFIT1* upon *AAVS1* KO (supplemental Figure 2F-G). However, in contrast to *METTL3* KO (Figure 5D-E), the expression of *IFIT1* and *IRF7* in *AAVS1* KO cells was significantly suppressed upon GSK595 treatment (supplemental Figure 2F-G). Taken together, this suggests that the observed effect of *METTL3* KO on the IFN pathway is distinct from any potential nonspecific effects associated with doxycycline-induced targeting.

Therefore, our findings indicate that activated IFN signaling confers resistance to PRMT5 inhibition in *METTL3*-depleted BPDCN cells and that this is potentially mediated by the upregulation of prominent IFN stimulated genes like *IFIT1* and *IRF7*.



**Figure 6. Stimulation with TLR7 agonist impairs the response of CAL-1 to GSK3326595.** Gene expression of (A) *IFITs* and (B) *IRFs* after stimulation with imiquimod. (C) Schematic illustration of the dual treatment regimen. (D) Phenotypic analysis of BPCDN surface markers after dual treatment (imiquimod + GSK595). (E) CAL-1 growth after stimulation with imiquimod and concurrent treatment with GSK595. (F) Lack of apoptosis activation upon treatment in imiquimod-stimulated cells. Gene expression of (G) *BCL-2*, (H) *IFIT1*, and (I) *IRF7* after imiquimod stimulation and GSK595 treatment (normalized to WT DMSO). Data are shown as mean  $\pm$  standard error of the mean of 3 independent experiments. \* $P < .05$ ; \*\* $P < .01$ ;  $P < .001$ .

## Stimulation with TLR7 agonist impairs CAL-1's response GSK595

Based on these results, we hypothesized that loss of *METTL3* relieves the inhibition of *IRF7* to promote transcriptional upregulation of *IFIT1*, which then results in increased IFN signaling. This increase in IFN response could be mediating resistance to PRMT5 inhibition due to an elevation in proinflammatory cytokines. To test this hypothesis, we administered TLR7 agonists to CAL-1 cells and examined if this renders CAL-1 cells less responsive to GSK595 treatment. We first verified the degree to which the various TLR7 agonists resiquimod (TLR7/8), gardiquimod (TLR7), and imiquimod (TLR7) stimulated IFN signaling in CAL-1 by measuring the changes in *IFIT1* and *IRF7* expression after stimulation (supplemental Figure 3B-C). From this, we chose imiquimod for further downstream analyses as it increased the expression of *IFIT1* and *IRF7* specifically in a dose-dependent manner (Figure 6A-B).

Next, we treated CAL-1 cells with imiquimod (6  $\mu$ g/mL) and GSK595 (0.31 and 5  $\mu$ M) concurrently (Figure 6C). To investigate if cotreatment (GSK595 + imiquimod) promotes terminal differentiation, we analyzed the surface expression of CD56, which is a key marker of pDC differentiation that is also known to be highly expressed in reactive pDCs.<sup>40</sup> No significant change in CD56 expression was observed across treatment conditions (Figure 6D), suggesting that imiquimod and GSK595 treatment does not affect the differentiation or activation status of BPDCN cells.

Notably, stimulation with imiquimod attenuated GSK595-mediated growth suppression of CAL-1 cells (Figure 6E). Correspondingly, imiquimod stimulation suppressed GSK595-induced apoptosis, as evidenced by the lower cleaved caspase-3 levels (Figure 6F) and higher antiapoptotic *BCL-2* expression (Figure 6G). Importantly, the attenuated effect of PRMT5 inhibition on CAL-1 cells was associated with increased *IFIT1* (Figure 6H) and *IRF7* (Figure 6I) expression relative to nonstimulated CAL-1 cells. Taken together, these results support our hypothesis that increased IFN signaling due to the absence of *METTL3* attenuates the response of *MYC*-driven BPDCN to PRMT5 inhibition.

## Discussion

BPDCN is a rare hematologic malignancy of unmet clinical need. The treatment of BPDCN remains a challenge, and consensus on an ideal therapeutic approach remains to be defined. In this study, we demonstrate the therapeutic potential of PRMT5 inhibition in BPDCN. We also identify m<sup>6</sup>A RNA modification as a downstream process modulated by PRMT5 via splicing and show that *METTL3* is crucial for BPDCN sensitivity to PRMT5 inhibition.

*MYC* expression status is a clinically relevant feature in BPDCN. The overexpression of *MYC* in BPDCN has been attributed to *MYC* rearrangement,<sup>41</sup> which is a recurrent cytogenetic abnormality with a prevalence of between 4% and 38%, depending on the population.<sup>42</sup> Since *MYC* rearrangement has been associated with poor prognosis,<sup>17,43</sup> such patients may benefit from novel therapeutic options. Previous studies have clarified the functional importance of *MYC* rearrangement and overexpression in BPDCN.<sup>5</sup> In agreement, we observed that GSK595-mediated cell growth inhibition was associated with a dose-dependent reduction in *MYC* expression. Paradoxically, a reduction in *MYC* expression upon *METTL3* KO was instead associated with an attenuated response to PRMT5

inhibition. Thus, our findings suggest that *MYC* overexpression and perhaps proliferative status, in general, may be a key determinant of BPDCN response to treatment with PRMT5 inhibitors. As such, further studies on the sensitivity of different BPDCN subsets to PRMT5 inhibition are warranted. Nonetheless, given that our study employed a patient-derived cell line that harbors the t(6;8) (p21;q24) *MYC* rearrangement,<sup>5,23</sup> our findings may be generalized to BPDCN with *MYC* rearrangement and overexpression.

RNA modification has the potential to influence clinical outcomes in hematologic cancers. Apart from AML,<sup>33</sup> the therapeutic significance of m<sup>6</sup>A RNA modification in other hematologic malignancies remain largely unexplored to date. Interestingly, we discovered that PRMT5 inhibition led to a loss of splicing fidelity and reduced expression of *METTL3*, a core component of the MTC that catalyzes m<sup>6</sup>A modification,<sup>21,44,45</sup> with a consequent reduction in m<sup>6</sup>A levels. In line with reports on the role of *METTL3* in myeloid differentiation and promoting the proliferation of leukemic stem cells,<sup>33,45</sup> we also show that BPDCN cell growth requires *METTL3*.

Intriguingly, our findings indicate that *METTL3*-depleted BPDCN cells are less sensitive to PRMT5 inhibition and reveal that upregulation of IFN signaling upon *METTL3* depletion contributes to this reduced sensitivity. In agreement, *METTL3* has been reported to negatively regulate IFN signaling in other cancer models via m<sup>6</sup>A modification of IFN target transcripts.<sup>46</sup> Interestingly, PRMT5 is also known to regulate IFN signaling, particularly in activated immune cells, where it is required for induction of IFN responses.<sup>35</sup> Thus, *METTL3* and PRMT5 have opposing roles in the regulation of IFN signaling. Taken together, our findings showcase how altered RNA modification may influence cellular response to PRMT5 inhibition due to modulation of IFN signaling.

Recurrent mutations in BPDCN are of potential clinical relevance to therapy with PRMT5 inhibitors. Loss-of-function mutations in the epigenetic modifier *TET2* are the most frequent mutations in BPDCN.<sup>16,19,47-49</sup> In pDCs, *TET2* was shown to promote *IRF7* expression and IFN production, while *TET2* loss disrupted splicing and conferred a growth advantage.<sup>19,50</sup> Since CAL-1 harbors a *TET2* loss-of-function mutation,<sup>23</sup> our findings suggest that *TET2*-mutant BPDCN is susceptible to PRMT5 inhibition, which may act by disrupting splicing and/or IFN signaling below the threshold required for BPDCN cell survival.

Splicing factors are another class of genes frequently mutated in BPDCN.<sup>19</sup> A recent study on BPDCN showed that mutations in the splicing factors *ZRSR2*, *SRSF2*, and *SF3B1* were associated with IR and impaired expression of *IRF7*.<sup>19</sup> Togami and colleagues recently reported the occurrence of *IRF7* IR in *ZRSR2*-mutant BPDCN cells.<sup>19</sup> Likewise, we detected the same IR event and reduced expression of *IRF7* upon PRMT5 inhibition, which suggests that *IRF7* expression is sensitive to splicing perturbations. The effect of impaired *IRF7* expression on BPDCN sensitivity to the dual TLR7/TLR8 agonist R848 (resiquimod) appears to be context-dependent. In *ZRSR2*-mutant BPDCN, impaired *IRF7* expression was associated with reduced pDC activation and resistance to R848-induced apoptosis. In contrast, we did not observe a significant impact on CAL-1 viability upon treatment with the TLR7-selective agonist imiquimod. This difference in sensitivity to TLR agonists may be attributed to a difference in agonistic activity between resiquimod (R848) and imiquimod. In our study, resiquimod concentrations as low as 0.5 to 1  $\mu$ g/mL induced a 60-fold

increase in *IFIT1* expression (supplemental Figure 2Bi), while there was a 2.5-fold increase in *IRF7* expression (supplemental Figure 2Ci). In comparison, 6  $\mu$ g/mL imiquimod only induced a 20-fold increase in *IFIT1* expression (supplemental Figure 2Biii), which better corresponds to the *IFIT1* levels observed upon METTL3 depletion (Figure 5D). Thus, the difference in BPDCN cell sensitivity to TLR agonists may be related to the significantly greater agonistic activity and IFN signaling induced by resiquimod than imiquimod. Additionally, there is a possibility that sensitivity to TLR agonists may be a feature of *ZRSR2*-mutant BPDCN.

Since our findings indicate that IFN signaling confers protection against GSK595-induced apoptosis, BPDCN with splicing factor mutations may be more sensitive to PRMT5 inhibition due to the cumulative suppression of *IRF7* expression and IFN signaling resulting from both PRMT5 inhibition and splicing factor mutations. Likewise, malignancies with splicing factor mutations were reported to be more susceptible to splicing factor inhibitors.<sup>51</sup> Therefore, PRMT5 inhibition may be generally effective against BPDCN with splicing factor mutations, irrespective of the METTL3 expression status.

Signaling pathway dysregulation in BPDCN is also of interest in the context of PRMT5 inhibition. The NF- $\kappa$ B pathway was reported to be aberrantly activated in BPDCN.<sup>52</sup> PRMT5 inhibition may counteract NF- $\kappa$ B pathway activation as PRMT5 has a role in facilitating NF- $\kappa$ B activity via dimethylation of the p65 subunit of NF- $\kappa$ B.<sup>53</sup> Apart from monotherapy, drug combination strategies that target different mechanisms may yield synergistic effects against BPDCN. Inhibition of the bromodomain and extra terminal protein BRD4 is a potential choice for combination therapy as its mechanism of action in BPDCN (disruption of the TCF4 transcriptional network that is essential for BPDCN<sup>54</sup>) appears to be distinct from that of PRMT5 inhibition.

BPDCN patients often present with skin lesions, and disease progression can involve other sites like bone marrow, spleen, and the central nervous system (CNS),<sup>55</sup> highlighting the importance of future therapies to be able to penetrate the CNS in order to have optimal therapeutic outcomes. The PRMT5 tool compound GSK3203591 has been shown to penetrate the blood–brain barrier and suppress the growth of glioblastoma.<sup>56</sup> In addition, 4-second generation PRMT5 inhibitors have also been reported to efficiently

curb GBM tumor growth in zebrafish with intracranial tumors.<sup>55</sup> These studies suggest that PRMT5 inhibition has the potential to treat BPDCN with CNS involvement. Therefore, follow-up studies on PRMT5 inhibitors in BPDCN should confirm the ability of PRMT5 inhibitors to target BPDCN in the CNS.

In conclusion, our findings highlight the potential relevance of RNA methylation status in the treatment of BPDCN and justify further investigation of the use of PRMT5 inhibitors in treating BPDCN patients. Specifically, subsequent studies should focus on identifying BPDCN subsets that are most susceptible to PRMT5 inhibition.

## Acknowledgments

The authors thank Takayoshi Matsumura (CSI-NUS, Singapore) for additional RNA-sequencing analyses.

This study was supported by the Singapore Ministry of Health's National Medical Research Council STaR Investigator Award, granted to T. Suda (NMRC/STaR/024/2019).

## Authorship

Contribution: M.R., D.Q.T., and T. Suda conceptualized and designed the research; M.R. performed experiments, analyzed and interpreted data, and wrote the manuscript; D.Q.T. performed experiments, interpreted data, and critically revised the manuscript; S.H.T. contributed essential materials, interpreted data, and revised the manuscript; R.Y., J.L., Y.L., and H.Y. performed key bioinformatical analyses; T. Sanda critically revised the manuscript; T. Suda supervised the research, acquired funding, and revised the manuscript; and all authors approved the final version of the manuscript for submission.

Conflicts-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: Y.L., 0000-0002-9316-2521; T.Sanda, 0000-0003-1621-4954.

Correspondence: Toshio Suda, Cancer Science Institute of Singapore, National University of Singapore, Singapore; e-mail: csits@nus.edu.sg.

## References

1. Beird HC, Khan M, Wang F, et al. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN). *Blood Cancer J*. 2019;9(12):99.
2. Economides MP, Konopleva M, Pemmaraju N. Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm. *Ther Adv Hematol*. 2019;10:2040620719874733.
3. Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm. *Hematology Am Soc Hematol Educ Program*. 2016;2016:16-23.
4. Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. *N Engl J Med*. 2019;380(17):1628-1637.
5. Kubota S, Tokunaga K, Umezaki T, et al. Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm. *Nat Commun*. 2019;10(1):1653.
6. Jen EY, Gao X, Li L, et al. FDA approval summary: tagraxofusp-erzs for treatment of blastic plasmacytoid dendritic cell neoplasm. *Clin Cancer Res*. 2020;26(3):532-536.
7. Guccione E, Richard S. The regulation, functions and clinical relevance of arginine methylation. *Nat Rev Mol Cell Biol*. 2019;20(10):642-657.
8. Jarrod J, Davies CC. PRMTs and arginine methylation: cancer's best-kept secret? *Trends Mol Med*. 2019;25(11):993-1009.



9. Yang Y, Bedford MT. Protein arginine methyltransferases and cancer. *Nat Rev Cancer*. 2013;13(1):37-50.
10. Xiao W, Chen X, Liu L, Shu Y, Zhang M, Zhong Y. Role of protein arginine methyltransferase 5 in human cancers. *Biomed Pharmacother*. 2019; 114:108790.
11. Tan DQ, Li Y, Yang C, et al. PRMT5 modulates splicing for genome integrity and preserves proteostasis of hematopoietic stem cells. *Cell Rep*. 2019;26(9):2316-2328.e6.
12. Gu Z, Gao S, Zhang F, et al. Protein arginine methyltransferase 5 is essential for growth of lung cancer cells. *Biochem J*. 2012;446(2):235-241.
13. Gullà A, Hideshima T, Bianchi G, et al. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. *Leukemia*. 2018;32(4):996-1002.
14. Jeon JY, Lee JS, Park ER, et al. Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells. *Oncol Rep*. 2018;40(1):536-544.
15. Watts JM, Bradley TJ, Thomassen A, et al. A phase I/II study to investigate the safety and clinical activity of the protein arginine methyltransferase 5 inhibitor GSK3326595 in subjects with myelodysplastic syndrome and acute myeloid leukemia. *Blood*. 2019;134:2656.
16. Sapienza MR, Abate F, Melle F, et al. Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. *Haematologica*. 2019;104(4):729-737.
17. Sakamoto K, Katayama R, Asaka R, et al. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. *Leukemia*. 2018;32(12):2590-2603.
18. Koh CM, Bezzi M, Low DH, et al. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. *Nature*. 2015; 523(7558):96-100.
19. Togami K, Chung SS, Madan V, et al. Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis. *Cancer Discov*. 2022;12(2):522-541.
20. Chen XY, Zhang J, Zhu JS. The role of m<sup>6</sup>A RNA methylation in human cancer. *Mol Cancer*. 2019;18(1):103.
21. Lin S, Choe J, Du P, Triboulet R, Gregory RI. The m(6)A methyltransferase METTL3 promotes translation in human cancer cells. *Mol Cell*. 2016; 62(3):335-345.
22. Xia T, Wu X, Cao M, et al. The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion. *Pathol Res Pract*. 2019;215(11):152666.
23. Maeda T, Murata K, Fukushima T, et al. A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma. *Int J Hematol*. 2005;81(2):148-154.
24. Ceribelli M, Hou ZE, Kelly PN, et al. A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. *Cancer Cell*. 2016;30(5):764-778.
25. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. *Nat Methods*. 2017;14(4):417-419.
26. Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. *F1000 Res*. 2015; 4:1521.
27. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol*. 2014;15(12): 550.
28. Zhu A, Ibrahim JG, Love MI. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. *Bioinformatics*. 2019;35(12):2084-2092.
29. Hamard PJ, Santiago GE, Liu F, et al. PRMT5 regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes. *Cell Rep*. 2018;24(10):2643-2657.
30. Liu Y, González-Porta M, Santos S, et al. Impact of alternative splicing on the human proteome. *Cell Rep*. 2017;20(5):1229-1241.
31. Radzishchanskaya A, Shliaha PV, Grinev V, et al. PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia. *Nat Struct Mol Biol*. 2019;26(11):999-1012.
32. Liu J, Ren D, Du Z, Wang H, Zhang H, Jin Y. m<sup>6</sup>A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression. *Biochem Biophys Res Commun*. 2018;502(4):456-464.
33. Qing Y, Su R, Chen J. RNA modifications in hematopoietic malignancies: a new research frontier. *Blood*. 2021;138(8):637-648.
34. <Interactions, localization, and phosphorylation of the m<sup>6</sup>A generating METTL3-METTL14-WTAP complex.pdf>.
35. Metz PJ, Ching KA, Xie T, et al. Symmetric arginine dimethylation is selectively required for mRNA splicing and the initiation of type I and type III interferon signaling. *Cell Rep*. 2020;30:1935-1950.e8.
36. Ning S, Pagano JS, Barber GN. IRF7: activation, regulation, modification and function. *Genes Immun*. 2011;12(6):399-414.
37. Pichlmair A, Lassnig C, Eberle CA, et al. IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. *Nat Immunol*. 2011;12(7):624-630.
38. Pidugu VK, Pidugu HB, Wu MM, Liu CJ, Lee TC. Emerging functions of human IFIT proteins in cancer. *Front Mol Biosci*. 2019;6:148.
39. Li T, Hu PS, Zuo Z, et al. METTL3 facilitates tumor progression via an m<sup>6</sup>A-IGF2BP2-dependent mechanism in colorectal carcinoma. *Mol Cancer*. 2019;18(1):112.

40. Wang W, Khoury JD, Miranda RN, et al. Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. *Haematologica*. 2021;106(4):1047-1055.
41. Boddu PC, Wang SA, Pemmaraju N, et al. 8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms. *Leuk Res*. 2018;66:73-78.
42. Garnache-Ottou F, Vidal C, Biichlé S, et al. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? *Blood Adv*. 2019;3(24):4238-4251.
43. Kato T, Itonaga H, Taguchi J, et al. Successful outcome of second allogeneic bone marrow transplantation for blastic plasmacytoid dendritic cell neoplasm with MYC locus rearrangement. *Leuk Res Rep*. 2019;11:31-33.
44. Tzelepis K, De Braekeleer E, Yankova E, et al. Pharmacological inhibition of the RNA m6a writer METTL3 as a novel therapeutic strategy for acute myeloid leukemia. *Blood*. 2019;134:403.
45. Vu LP, Pickering BF, Cheng Y, et al. The N<sup>6</sup>-methyladenosine (m<sup>6</sup>A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. *Nat Med*. 2017;23(11):1369-1376.
46. Wang L, Hui H, Agrawal K, et al. m<sup>6</sup>A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. *EMBO J*. 2020;39(20):e104514.
47. Alayed K, Patel KP, Konoplev S, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. *Am J Hematol*. 2013;88(12):1055-1061.
48. Batta K, Bossenbroek HM, Pemmaraju N, et al. Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. *Leukemia*. 2021;35(11):3299-3303.
49. Renosi F, Roggy A, Giguélay A, et al. Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. *Blood Adv*. 2021;5(5):1540-1551.
50. Ma S, Wan X, Deng Z, et al. Epigenetic regulator CXXC5 recruits DNA demethylase Tet2 to regulate TLR7/9-elicited IFN response in pDCs. *J Exp Med*. 2017;214(5):1471-1491.
51. Lee SC, Dvinge H, Kim E, et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. *Nat Med*. 2016;22(6):672-678.
52. Sapienza MR, Fuligni F, Agostinelli C, et al; AIRC 5xMille consortium 'Genetics-driven targeted management of lymphoid malignancies and the Italian Registry on Blastic Plasmacytoid Dendritic Cell Neoplasm. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-κB pathway inhibition. *Leukemia*. 2014;28(8):1606-1616.
53. Wei H, Wang B, Miyagi M, et al. PRMT5 dimethylates R30 of the p65 subunit to activate NF-κB. *Proc Natl Acad Sci USA*. 2013;110(33):13516-13521.
54. Sakaguchi T, Yoshino H, Sugita S, et al. Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma. *Oncotarget*. 2018;9(33):23003-23017.
55. Pemmaraju N, Wilson NR, Khoury JD, et al. Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. *Blood*. 2021;138(15):1373-1377.
56. Sachamitr P, Ho JC, Ciamponi FE, et al. PRMT5 inhibition disrupts splicing and stemness in glioblastoma. *Nat Commun*. 2021;12(1):979.